Aug. 6 at 4:16 PM
$INKT NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NSDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T-cell (iNKT) therapies for cancer and immune disorders, today announced initial observations from patients treated with agenT-797 in its ongoing Phase 2 study in patients with severe hypoxemic pneumonia.
Severe lung injury has high mortality and no approved therapy proven to reduce it.
Initial reports: agenT-797-treated patients were alive, with substantially improved hemodynamics, mental status and oxygenation at Day 28. Microbiological data indicated control of the baseline infections and serum and bronchoalveolar lavage analyses showed reduced inflammatory markers and biological changes associated with immune recovery, epithelial repair and pulmonary vascular recovery. No major serious adverse events attributed to agenT-797 were reported in these first treated patients.
